Skip Navigation LinksHome > June 2005 - Volume 11 - Issue 3 > Immunologic Mechanisms in the Pathogenesis of Rheumatoid Art...
JCR: Journal of Clinical Rheumatology:
doi: 10.1097/01.rhu.0000166673.34461.33
Supplement Article

Immunologic Mechanisms in the Pathogenesis of Rheumatoid Arthritis

Firestein, Gary S. MD

Free Access
Article Outline
Collapse Box

Author Information

From the Department of Medicine and the Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, California.

Reprints: Gary S. Firestein, Professor of Medicine, Chief of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, 9500 Gilman Drive BSB, Room 5098, Mail Code 0656, La Jolla, CA 92093. E-mail:

Collapse Box


Although much is known about the etiology and pathogenesis of rheumatoid arthritis (RA), our understanding of the immune pathways remains incomplete. The observed clinical and pathologic manifestations result from activation of several interrelated immune pathways. Current concepts of RA pathogenesis, supported by animal models, laboratory studies, and clinical observation, have reestablished and revised some of the original views. Early proposals emphasized the importance of autoantibodies and immune complexes in the initiation of RA, suggested a role for T cells in the inflammatory response characteristic of RA, and based disease perpetuation on an imbalance in the cytokine networks. We now recognize that each of these interrelated mechanisms significantly contributes to RA pathogenesis, including T cells that can help initiate and perpetuate the disease. This article reviews the major components and immune pathways involved in RA and briefly discusses the animal models that contribute to our understanding. Although a unified theory of RA pathogenesis may not be possible at this time, a paradigm is presented that considers the immune pathways that contribute to disease progression and joint destruction. These pathways may have important implications for treatment, because their modulation by biologic response modifiers (BRMs) directed toward specific targets provides benefits to patients with RA. BRMs are a new class of therapeutic agents derived from biologically active molecules and designed to modulate specific immune or inflammatory pathways. Although currently approved BRMs still have limitations, choosing an appropriate target, possibly early rather than late in the immune response, might result in new and improved therapies for RA.

Rheumatoid arthritis (RA) is a complex inflammatory disease of synovial joints, especially the small joints of the hands and feet, that is characterized by joint destruction and chronic disability. With a population point prevalence of 1%,1 RA is responsible for a significant socioeconomic burden.2 This burden results not only from direct medical costs associated with substantial health resource utilization, but also from high indirect and intangible costs related to lost productivity and decreased quality of life. Recent estimates suggest that indirect costs may account for as much as two thirds of the almost $16 billion annual cost of RA.2

Although rheumatic diseases were recognized at the time of Hippocrates, what has come to be known as RA was first recognized in the 17th century and named by Garrod in 1859. It was definitively described as a clinical entity by Charles Short in 1957. Its complexity was immediately recognized, but despite much immunologic research and the identification of multiple cells and pathways that contribute to its pathogenesis, the underlying etiology and pathogenesis are still not completely understood.

This review discusses our present knowledge of the pathogenic mechanisms of RA. Although we have revisited some of the early views regarding the mechanisms that support inflammation and joint destruction, significant progress has been made in our understanding of the disease. This understanding can be of benefit in developing appropriate therapy through modulation of immune pathways.

Back to Top | Article Outline


Initial Theories: Autoimmunity and T-Cell Involvement

Views of RA have undergone several incarnations as new mechanisms and pathways have been uncovered and added to the growing immunologic literature regarding its pathogenesis. RA was initially considered an autoimmune disease based in large part on the identification of rheumatoid factor (RF) in the sera of patients with RA and the characterization of these factors as autoantibodies.3 Zvaifler4 and others subsequently proposed that RA represents a localized immune complex disease characterized by production of RF in the synovium, the formation of RF-immune complexes that fix complement with the ensuing consumption of complement within the joint, and the recruitment of a variety of cells (eg, T cells, B cells, macrophages) that become activated and contribute to inflammation and joint damage. The immune-complex hypothesis was reasonable, especially because the presence of RF was determined to be predictive of more aggressive disease. However, it did not account for the absence of RF in some patients with RA, the presence of RF in patients with other diseases, the presence of RF in a proportion of normal individuals, and other features of the disease.

The search for additional mechanisms implicated a role for T cells in RA pathogenesis and resulted in the identification of immunogenetic components. Using allogeneic mixed lymphocyte reactions, Stastny et al5 demonstrated a relationship between RA and specific human leukocyte antigen (HLA)-DR genes of the major histocompatability complex (MHC). This was the first evidence of a genetic component, and it was a notable finding because HLA is a key molecule responsible for the presentation of antigen to T cells by antigen-presenting cells (APCs) such as macrophages and dendritic cells. Antigen presentation is also one of the signals required for T-cell costimulation and activation, early events in the adaptive immune response.

It subsequently became clear that not only is HLA integral to the immune response, but that the RA associate maps to a specific gene locus coding for the third hypervariable region of the DRβ chain.6 This epitope may predict susceptibility and disease severity.7 One possible mechanism is that this molecule binds an arthritogenic peptide resulting in T-cell activation and inflammation in susceptible individuals. However, caveats associated with this mechanism included the lack of identification of a specific reactive peptide, the existence of heterogeneous allele associations, and the multiple functions of HLA in the immune response. Nevertheless, the implication of T cells in the orchestration of RA pathogenesis was a major breakthrough and is supported by the fact that many of the animal models of arthritis are T cell-dependent (eg, collagen- and adjuvant-induced arthritis).

Back to Top | Article Outline
Cytokine Pathways

By the mid-1980s, cytokines produced in a variety of immune and inflammatory cells had been identified, and these molecules were considered prominent in the RA disease process. A chaotic cytokine network was simplified by the characterization of a regulatory network that took into account the major cell types in the synovium, their products, and their actions. For instance, the production of the T cell–associated cytokines interferon-γ (IFN-γ) and interleukin-2 (IL-2) within the synovium is relatively low in RA.8 The fibroblast- and macrophage-like synoviocytes in the intimal lining of the synovium produce factors that activate adjacent cells to maintain the inflammatory response, with T cells as well as B cells and macrophages accumulating in the sublining layer.9 The predominance of these macrophage- and fibroblast-derived cytokines8 pointed to a non-T-cell mechanism for rheumatoid synovitis. The cytokine network was subsequently proposed as a perpetuating mechanism in RA,10 and the imbalance between proinflammatory and antiinflammatory cytokines became the focus of pathogenic mechanisms in RA.

Strong support for the role of the cytokine network in RA was provided by the development and approval of the first biologic response modifiers (BRMs). These BRMs, which specifically target cytokines involved in the inflammatory response, include the anti–tumor necrosis factor (TNF-α) agents etanercept, infliximab, and adalimumab, and the IL-1 inhibitor anakinra. That these BRMs are effective in the management of RA and have been beneficial in a proportion of patients, providing not only symptomatic relief, but also slowing radiographic progression, confirms the importance of cytokines. However, these agents are dramatically effective in only approximately 40% of patients, and even in these patients, the requirement for continuous therapy suggests that additional stimuli are required to orchestrate the regulation of cytokine production.

Back to Top | Article Outline


Autoantibodies Redux

Renewed interest in autoantibodies as precipitating factors in RA pathogenesis resulted in part from the serendipitous development of a spontaneous mouse model of arthritis that is mediated by immune complex formation. The K/BxN mouse is a transgenic mouse characterized by a chronic erosive polyarthritis that shows similarities to human inflammatory RA, including pannus formation, synoviocyte proliferation, and synovitis.11 Propagation of this arthritis is dependent on B-cell secretion of arthritogenic autoantibodies.12 These autoantibodies bind to the self-antigen glucose-6-phosphate isomerase (GPI), a ubiquitously expressed cytosolic enzyme involved in glycolysis.13 The disease in these mice initially starts as a T cell-dependent response to GPI in which autoreactive T cells recruit anti-GPI B cells, which then differentiate into plasma cells producing arthritogenic autoantibodies (anti-GPI-IgG). The subsequent initiation of synovitis is solely dependent on these autoantibodies, because transfer of sera or purified anti-GPI antibody from K/BxN mice into naive mice results in the transient development of arthritic joints.11,12,14 Repeated administration of K/BxN serum or antibody is required to maintain the disease. The proposed mechanism for these effects is induction of the inflammatory cascade resulting from the formation of GPI–anti-GPI immune complexes on articular surfaces.15 The inflammatory cascade appears to be primarily mediated by the alternative complement pathway,15 but the K/BxN model is also clearly dependent on the cytokine network. In vivo studies in cytokine knockout mice suggest an absolute requirement for IL-1 and a lesser role for TNF in disease development.16 This model not only demonstrates the importance of autoantibodies as a catalyst for the inflammatory response, but also highlights the role of T cells and shows that there is a clear relationship among the various proposed pathogenic mechanisms.

Although the presence of these autoantibodies suggests a role of B cells in RA (Fig. 1), a joint-specific self-antigen may not be a prerequisite for induction of RA. In the case of GPI, its actual role in human RA is unclear, because there is a low prevalence and an absence of specificity of GPI antibodies in RA.17 Hence, GPI–anti-GPI immune complexes are not likely to be a major driving force in disease pathogenesis. There are many other putative antigens implicated in RA, including heat shock proteins, collagen, heavy chain binding protein, and cyclic citrullinated peptides (CCPs).18 These molecules could contribute to the pathogenesis of RA, because the resulting immune complex formation can potentially promote complement fixation and activation of immune cells (Fig. 1). However, autoantibodies are not likely to be the sole etiologic agents, because autoreactivity often precedes clinical RA by many years.19 In particular, anti-CCP antibodies might be predictive of RA, with presence in sera predating onset of symptoms.20 Anti-CCP antibodies also have >90% specificity for RA21 with a high predictive value for development of clinical disease, disease severity, and radiographic damage.19,20,22–24

Figure 1
Figure 1
Image Tools
Back to Top | Article Outline
T-Cell Involvement

Just as autoantibodies and immune complexes are being reestablished in the hierarchy of immunoinflammatory events in RA, T cells have also been implicated as primary mediators in the orchestration of RA. This role for T cells represents one of the latest developments in our understanding of RA and is important not only from the mechanistic standpoint, but also from the clinical perspective.25

In a manner similar to that of autoantibodies discussed here, the concept of a central role for T cells was supported by another spontaneous mouse model. The SKG mouse is a T cell-dependent model of inflammatory arthritis that has clinical and histologic similarities with human RA.25,26 In the SKG mouse, a mutation in the ZAP-70 signal transduction gene involved in T-cell activation results in abnormal thymic selection of autoreactive T cells. Instead of being deleted to prevent autoimmunity, there is positive selection of these autoreactive T cells, which survive and become arthritogenic.

Although the SKG model suggests that T cells can spontaneously cause inflammatory arthritis in RA, to understand how this occurs, it is important to understand that activation of naive T cells requires 2 distinct but contemporaneous ligation events (Fig. 2). 27 The first event consists of presentation by an APC of an MHC–antigen complex with reciprocal binding to the T-cell receptor. The second signal occurring in temporal proximity is ligation of a costimulation molecule on the APC with its cognate receptor molecule on the T cell. Binding of the MHC–antigen complex to the T cell without costimulation results in hyporesponsive T cells (ie, anergy).28 In contrast, binding of both costimulatory signals results in T-cell activation with the consequences of T-cell antigen responsiveness. Several costimulatory pairs have been described, some of which activate T cells and some of which attenuate the T-cell response. Of the pairs that activate T cells, CD28 and CD80/CD86 are among the best characterized.27 This pathway is the target for abatacept, a new BRM that interferes with costimulation. Although this approach and its clinical implications are discussed elsewhere in this supplement,29 the clinical efficacy observed using costimulation modulation supports a role of T cells in many patients with RA.

Figure 2
Figure 2
Image Tools

T cells may contribute to the inflammatory response because they not only have specific effector functions, but they also activate or interact with other cells that perpetuate inflammation and joint destruction (Fig. 3). These interactions include those with B cells, which may then be induced to produce autoantibodies; macrophages, fibroblast-like synoviocytes, and chondrocytes, all of which can release proteases and other effector molecules; and osteoclasts.9 These latter cells are of particular importance because they are responsible for bone resorption and their activation accelerates joint destruction in patients with RA.30

Figure 3
Figure 3
Image Tools

There is also intersection between T cells and the cytokine pathway through T cell-derived cytokines and cytokines released by other T cell-activated immune cells. Two T cell-derived cytokines of potential importance in RA are IFN-γ and IL-17. Although only small amounts of IFN-γ are produced by synovial T cells,8,31 the presence of this cytokine could be important. First, IFN-γ serves as a marker for the subset of activated T cells known as TH1 helper cells. These cells promote and amplify autoimmune diseases, and it may be a shift in the ratio of TH1 and TH2 cells that helps perpetuate pathogenic mechanisms.32,33 IFN-γ also has a direct effect on inflammation by increasing MHC class II expression as well as priming macrophages to produce inflammatory and tissue-damaging mediators such as TNF-α, proteases, reactive oxygen species, and nitric oxide.34

Another notable T cell-derived cytokine detected in RA synovium is IL-17. This cytokine, which shares many functions with IL-1 and TNF-α, is produced in rheumatoid synovium by T cells.35,36 The consequences of IL-17 action have led to the suggestion that it might serve as a “missing link” between T-cell accumulation/activation and the downstream mechanisms leading to inflammation and joint destruction.35 IL-17 can amplify the production of proinflammatory cytokines by fibroblasts and macrophages and can also promote cell adhesion molecules, thereby enhancing infiltration of inflammatory cells into the joint. It also induces production of matrix metalloproteinases (MMPs) and shifts the balance of bone metabolism toward osteoclastogenesis with subsequent bone resorption.35

Although IL-17 by itself can induce MMP production and cause cartilage destruction, suboptimal concentrations are synergistic when combined with the proinflammatory cytokines TNF-α and IL-1.37 Based on this range of activities, IL-17 has been considered a potential target for therapy. In fact, treatment of a mouse model of arthritis with a neutralizing antibody against IL-17 results in reduced inflammation and joint damage.38

If T cells produce cytokines and perform other effector functions in the joint, the inciting antigen is clearly relevant. Although many identified antigens have been considered such as RF, GPI, CCP, and others as previously mentioned, no single antigen fits all the requirements for explaining the disease.9 Indeed, initiating antigens might be distinct from perpetuating epitopes. Either antigen spread or antigen replacement might be a driving force in established disease. Furthermore, as also previously suggested with regard to GPI, the inciting stimulus need not be a joint-associated antigen. Although some of the currently identified autoantibodies are joint-specific such as type-2 collagen and proteoglycans, RF and CCP are systemic antigens that have been implicated.9

Back to Top | Article Outline
The Significance of Synoviocytes

In addition to the previously mentioned immune cells, recent work has identified a subpopulation of activated synovial fibroblasts that are present in RA and have characteristics that clearly distinguish them from other synovial fibroblasts.39,40 These fibroblasts within the RA synovium are more aggressive than normal or osteoarthritis synoviocytes. Their activation induces an increase in adhesion molecules, which enhances their attachment to articular cartilage and increases their invasiveness into the extracellular matrix. When activated, they also release MMPs and other proteolytic enzymes, which contribute to joint degradation by digesting matrix proteins such as collagen and proteoglycans. Additionally, the RA synovial fibroblasts appear to enhance T- and B-cell survival in the synovium by preventing apoptosis, potentially prolonging the immune effector functions of these cells.

Evidence suggests that in RA, this subpopulation of synovial fibroblasts might become permanently imprinted to express the more aggressive phenotype. When coimplanted with normal human cartilage in severe combined immunodeficient mice, they retain their aggressive behavior even in the absence of other inflammatory cells.41 The factors initiating activation and imprinting have not been fully characterized, although cytokine-dependent and -independent mechanisms have been described.40

Back to Top | Article Outline


After many years of experimental and clinical investigation into the pathogenesis of RA, we have a better, albeit still incomplete, understanding of the disease process. Interestingly, we have come full circle in our concepts, with the roles of immune complexes and T cells that were initially postulated to be central to RA pathogenesis again coming into focus as primary mediators in the initiation and perpetuation of the disease.

Although RA is a complex disease with multiple interacting mechanisms that contribute to inflammation and joint destruction, a possible paradigm that takes into account the major features can be described as shown in Figure 4. In this model, both predetermined and random events contribute to the initiation of the disease. The predetermined aspect is the genetic component, which suggests that certain individuals carry a genotype for autoreactivity that may precede disease onset. The random aspect is represented by environmental influences that might activate innate immunity. This primordial defense system is an evolutionary adaptation that enables rapid recognition and elimination of pathogens and is considered the first line of an organism's immune defense.

Figure 4
Figure 4
Image Tools

Processing an unspecified but not necessarily rheumatoid-specific antigen by dendritic cells and presentation to T cells in conjunction with the costimulatory signal activates the T cells that then help orchestrate many of the downstream pathways. This processing and presentation of antigen likely occurs in central lymphoid organs and initiates the adaptive immune response, an organism's second line of defense that results in expansion of cell populations recognizing specific antigens. The initiation of adaptive immunity produces a clonal expansion of T cells with subsequent migration to the synovium where cytokines are produced and where the T cells interact with synoviocytes, macrophages, and B cells to promote inflammation. Under appropriate conditions, loss of tolerance related to either genetic predisposition or the T-cell repertoire can result in an autoimmune response to particular antigens newly exposed during inflammatory degradation of the joint.

With the identification of multiple cell types and various cytokines providing opportunities for new interventions, these concepts have therapeutic implications and have shaped our current approach to RA management. Furthermore, the complexity and redundancy of the regulatory mechanisms combined with the observed interpatient variability in the disease process explains why some patients may respond to a particular therapy whereas others do not, especially when targeting pathways downstream of key regulators of immunologic events.

The ability to construct biologically active molecules has resulted in the introduction of BRMs as therapeutic agents. By modulating immune and cellular responses, BRMs have expanded our resources for therapy as well as for further investigation of the disease process. Although currently approved BRMs represent a major step forward in the treatment of RA, demonstrating both symptomatic efficacy and disease modification, they are not without limitations. Choosing an appropriate therapeutic target is crucial to bringing greater benefits to more patients. It is possible that modulation of selected events early rather than late in the immune response can have the effect of modulating pathways that are of particular importance in the pathogenic process. Agents currently in clinical trials such as abatacept (discussed in this supplement by Kremer29), as well as many still in development (reviewed in this supplement by Genovese42), have generated optimism that we may eventually control the progressive course of RA, reducing both the economic and patient burden.

Back to Top | Article Outline


1. Sangha O. Epidemiology of rheumatic disease. Rheumatology (Oxford). 2000;39(suppl 2):3–12.

2. Dunlop DD, Manheim LM, Yelin EH, et al. The costs of arthritis. Arthritis Rheum. 2003;49:101–113.

3. Franklin EC, Holman HR, Muller-Eberhard HJ, et al. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med. 1957;105:425–438.

4. Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol. 1973;16:265–336.

5. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest. 1976;57:1148–1157.

6. Nepom GT, Byers P, Seyfried C, et al. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum. 1989;32:15–21.

7. Weyand CM, Hicok KC, Conn DL, et al. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992;117:801–806.

8. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990;144:3347–3353.

9. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361.

10. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 1990;33:768–773.

11. Kouskoff V, Korganow AS, Duchatelle V, et al. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996;87:811–822.

12. Korganow AS, Ji H, Mangialaio S, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999;10:451–461.

13. Matsumoto I, Staub A, Benoist C, et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 1999;286:1732–1735.

14. Ditzel HJ. The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol Med. 2004;10:40–45.

15. Matsumoto I, Maccioni M, Lee DM, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002;3:360–365.

16. Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002;196:77–85.

17. Matsumoto I, Lee DM, Goldbach-Mansky R, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 2003;48:944–954.

18. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2002;4:87–93.

19. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380–386.

20. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–2749.

21. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273–281.

22. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000;43:1831–1835.

23. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003;62:120–126.

24. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50:709–715.

25. Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest. 2004;114:471–474.

26. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003;426:454–460.

27. Stuart RW, Racke MK. Targeting T cell costimulation in autoimmune disease. Exp Opin Ther Targets. 2002;6:275–289.

28. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305–334.

29. Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol. 2005;11(suppl):S55–S62.

30. Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res. 2002;4:281–289.

31. Steiner G, Tohidast-Akrad M, Witzmann G, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford). 1999;38:202–213.

32. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787–793.

33. Dolhain RJ, van der Heiden AN, ter Haar NT, et al. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:1961–1969.

34. Janeway CA, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease, 5th ed. New York: Taylor & Francis Group; 2001.

35. Stamp LK, James MJ, Cleland LG. Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol. 2004;82:1–9.

36. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42:963–970.

37. Koshy PJ, Henderson N, Logan C, et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis. 2002;61:704–713.

38. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50:650–659.

39. Pap T, Muller-Ladner U, Gay RE, et al. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2:361–367.

40. Ospelt C, Neidhart M, Gay RE, et al. Synovial activation in rheumatoid arthritis. Front Biosci. 2004;9:2323–2334.

41. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996;149:1607–1615.

42. Genovese MC. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol. 2005;11(suppl):S45–S54.

Cited By:

This article has been cited 55 time(s).

Journal of Nuclear Medicine
In Vivo Imaging of Cell Proliferation Enables the Detection of the Extent of Experimental Rheumatoid Arthritis by 3 '-Deoxy-3 '-F-18-Fluorothymidine and Small-Animal PET
Fuchs, K; Kohlhofer, U; Quintanilla-Martinez, L; Lamparter, D; Kotter, I; Reischl, G; Rocken, M; Pichler, BJ; Kneilling, M
Journal of Nuclear Medicine, 54(1): 151-158.
Clinical and Experimental Immunology
High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis
Wang, J; Shan, Y; Jiang, Z; Feng, J; Li, C; Ma, L; Jiang, Y
Clinical and Experimental Immunology, 174(2): 212-220.
Clinical and Experimental Pharmacology and Physiology
Effects of yunke (technetium-99 conjugated with methylene diphosphonate; (99)tc-mdp) and/or colloidal chromic phosphate phosphonium-32, alone and in combination, in rats with adjuvant arthritis
Wang, LM; Gu, QR; Xu, Y; Li, SH; Gui, JC; Yang, JP; Yao, QQ; Ji, Y
Clinical and Experimental Pharmacology and Physiology, 35(1): 23-28.

Journal of Rheumatology
Downregulation of RCAS1 and upregulation of cytotoxic T cells affects synovial proliferation and apoptosis in rheumatoid arthritis
Yoshida, S; Higuchi, F; Ishibashi, Y; Goto, M; Sugita, Y; Nomura, Y; Karube, K; Shimizu, K; Aoki, R; Komatani, H; Hashikawa, K; Kimura, Y; Nakashima, M; Nagata, K; Ohshima, K
Journal of Rheumatology, 35(9): 1716-1722.

Journal of Gene Medicine
Intra-articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice
Bloquel, C; Denys, A; Boissier, MC; Apparailly, F; Bigey, P; Scherman, D; Bessis, N
Journal of Gene Medicine, 9(): 986-993.
Arthritis and Rheumatism
The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature
Coelho, FM; Pinho, V; Amaral, FA; Sachs, D; Costa, VV; Rodrigues, DH; Vieira, AT; Silva, TA; Souza, DG; Bertini, R; Teixeira, AL; Teixeira, MM
Arthritis and Rheumatism, 58(8): 2329-2337.
Arthritis and Rheumatism
The C-786/T single-nucleotide polymorphism in the promoter of the gene for endothelial nitric oxide synthase - Insensitivity to physiologic stimuli as a risk factor for rheumatoid arthritis
Melchers, I; Blaschke, S; Hecker, M; Cattaruzza, M
Arthritis and Rheumatism, 54(): 3144-3151.
Clinical and Experimental Medicine
Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis
Torres-Carrillo, N; Torres-Carrillo, NM; Martinez-Bonilla, GE; Vazquez-Del Mercado, M; Palafox-Sanchez, CA; Oregon-Romero, E; Bernard-Medina, AG; Rangel-Villalobos, H; Munoz-Valle, JF
Clinical and Experimental Medicine, 9(3): 223-228.
TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines
Kuai, J; Gregory, B; Hill, A; Pittman, DD; Feldman, JL; Brown, T; Carito, B; O'Toole, M; Ramsey, R; Adolfsson, O; Shields, KM; Dower, K; Hall, JP; Kurdi, Y; Beech, JT; Nanchahal, J; Feldmann, M; Foxwell, BM; Brennan, FM; Winkler, DG; Lin, LL
Rheumatology, 48(): 1352-1358.
Annual Review of Immunology
Immunity to citrullinated proteins in rheumatoid arthritis
Klareskog, L; Ronnelid, J; Lundberg, K; Padyukov, L; Adfredsson, L
Annual Review of Immunology, 26(): 651-675.
Annals of the Rheumatic Diseases
Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors
Jorgensen, KT; Wiik, A; Pedersen, M; Hedegaard, CJ; Vestergaard, BF; Gislefoss, RE; Kvien, TK; Wohlfahrt, J; Bendtzen, K; Frisch, M
Annals of the Rheumatic Diseases, 67(6): 860-866.
Brain Behavior and Immunity
Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis
Gutierrez-Canas, I; Juarranz, Y; Santiago, B; Martinez, C; Gomariz, RP; Pablos, JL; Leceta, J
Brain Behavior and Immunity, 22(3): 312-317.
Journal of Immunotoxicology
Immunodiagnostics: Evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers
Kowalski, RJ; Zeevi, A; Mannon, RB; Britz, JA; Carruth, LM
Journal of Immunotoxicology, 4(3): 225-232.
Proceedings of the National Academy of Sciences of the United States of America
Positional cloning of the Igl genes controlling rheumatoid factor production and allergic bronchitis in rats
Rintisch, C; Ameri, J; Olofsson, P; Luthman, H; Holmdahl, R
Proceedings of the National Academy of Sciences of the United States of America, 105(): 14005-14010.
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis
Segal, B; Rhodus, NL; Patel, K
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 106(6): 778-787.
Gene Therapy and Molecular Biology
Gene therapy for arthritis: defining novel gene targets
Malemud, CJ
Gene Therapy and Molecular Biology, 11A(): 27-35.

Clinical Immunology
Regulation of autoimmune arthritis by the pro-inflammatory cytokine interferon-gamma
Kim, EY; Chi, HH; Bouziane, M; Gaur, A; Moudgil, KD
Clinical Immunology, 127(1): 98-106.
Arthritis Research & Therapy
Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane
Huber, R; Hummert, C; Gausmann, U; Pohlers, D; Koczan, D; Guthke, R; Kinne, RW
Arthritis Research & Therapy, 10(4): -.
Current Drug Targets
The Role of Cartilage Oligomeric Matrix Protein (COMP) in Skeletal Disease
Posey, KL; Hecht, JT
Current Drug Targets, 9(): 869-877.

Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice
Li, HZ; Gong, X; Zhang, L; Zhang, Z; Luo, FL; Zhou, QX; Chen, J; Wan, JY
Phytomedicine, 16(): 538-546.
Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes
Byun, HS; Song, JK; Kim, YR; Piao, L; Won, M; Park, KA; Choi, BL; Lee, H; Hong, JH; Park, J; Seok, JH; Lee, YJ; Kang, SW; Hur, GM
Rheumatology, 47(3): 301-308.
Arthritis and Rheumatism
Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis - Putative involvement in the pathogenesis of rheumatoid arthritis
Klingelhofer, J; Senolt, L; Baslund, B; Nielsen, GH; Skibshoj, I; Pavelka, K; Neidhart, M; Gay, S; Ambartsumian, N; Hansen, BS; Petersen, J; Lukanidin, E; Grigorian, M
Arthritis and Rheumatism, 56(3): 779-789.
Rheumatology International
The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis
Torres-Carrillo, NM; Torres-Carrillo, N; Mercado, MVD; Delgado-Rizo, V; Oregon-Romero, E; Parra-Rojas, I; Munoz-Valle, JF
Rheumatology International, 28(4): 355-360.
Clinical Immunology
Role of GADD45 beta in the regulation of synovial fluid T cell apoptosis in rheumatoid arthritis
Du, F; Wang, L; Zhang, Y; Jiang, W; Sheng, HM; Cao, Q; Wu, JJ; Shen, BH; Shen, TW; Zhang, JWZ; Bao, C; Li, DS; Li, NL
Clinical Immunology, 128(2): 238-247.
Plos One
Multiparameter Phospho-Flow Analysis of Lymphocytes in Early Rheumatoid Arthritis: Implications for Diagnosis and Monitoring Drug Therapy
Galligan, CL; Siebert, JC; Siminovitch, KA; Keystone, EC; Bykerk, V; Perez, OD; Fish, EN
Plos One, 4(8): -.
ARTN e6703
Human Immunology
Monocyte dysfunction in Sydenham's chorea patients
Torres, KC; Dutra, WO; de Rezende, VB; Cardoso, F; Gollob, KJ; Teixeira, AL
Human Immunology, 71(4): 351-354.
Genes and Immunity
Finemapping of the arthritis QTL Pia7 reveals co-localization with Oia2 and the APLEC locus
Rintisch, C; Kelkka, T; Norin, U; Lorentzen, JC; Olofsson, P; Holmdahl, R
Genes and Immunity, 11(3): 239-245.
Expert Opinion on Therapeutic Targets
Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs
Malemud, CJ; Miller, AH
Expert Opinion on Therapeutic Targets, 12(2): 171-183.
Pathology & Oncology Research
Alterations of the CD4(+), CD8(+) T cell subsets, interleukins-1 beta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: Preliminary observations
Hussein, MR; Fathi, NA; El-Din, AME; Hassan, HI; Abdullah, F; Al-Hakeem, E; Backer, EA
Pathology & Oncology Research, 14(3): 321-328.
Clinical Immunology
Analyses of immunosenescent markers in patients with autoimmune disease
Thewissen, M; Somers, V; Venken, K; Linsen, L; Van Paassen, P; Geusens, P; Damoiseaux, J; Stinissen, P
Clinical Immunology, 123(2): 209-218.
Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis
Schmitt-Sody, M; Metz, P; Gottschalk, O; Birkenmaier, C; Zysk, S; Veihelmann, A; Jansson, V
Platelets, 18(5): 365-372.
Inflammation Research
Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis
Schmitt-Sody, M; Metz, P; Gottschalk, O; Zysk, S; Birkenmaier, C; Goebl, M; Pellengahr, CVS; Veihehnann, A; Jansson, V
Inflammation Research, 56(): 414-420.
Arthritis and Rheumatism
Detection of Arthritis-Susceptibility Loci, Including Ncf1, and Variable Effects of the Major Histocompatibility Complex Region Depending on Genetic Background in Rats
Rintisch, C; Forster, M; Holmdahl, R
Arthritis and Rheumatism, 60(2): 419-427.
Kallikreins, kininogens and kinin receptors on circulating and synovial fluid neutrophils: role in kinin generation in rheumatoid arthritis
Cassim, B; Shaw, OM; Mazur, M; Misso, NL; Naran, A; Langlands, DR; Thompson, PJ; Bhoola, KD
Rheumatology, 48(5): 490-496.
Lasers in Surgery and Medicine
Low Level Light Effects on Inflammatory Cytokine Production by Rheumatoid Arthritis Synoviocytes
Yamaura, M; Yao, M; Yaroslavsky, I; Cohen, R; Smotrich, M; Kochevar, IE
Lasers in Surgery and Medicine, 41(4): 282-290.
Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment
Miellot-Gafsou, A; Biton, J; Bourgeois, E; Herbelin, A; Boissier, MC; Bessis, N
Immunology, 130(2): 296-306.
Arthritis Research & Therapy
Celastrus aculeatus Merr. suppresses the induction and progression of autoimmune arthritis by modulating immune response to heat-shock protein 65
Tong, L; Moudgil, KD
Arthritis Research & Therapy, 9(4): -.
Journal of Internal Medicine
Th17 cells in rheumatoid arthritis and systemic lupus erythematosus
Pernis, AB
Journal of Internal Medicine, 265(6): 644-652.
Clinica Chimica Acta
Growth hormone, VEGF and FGF: Involvement in rheumatoid arthritis
Malemud, CJ
Clinica Chimica Acta, 375(): 10-19.
Journal of Immunology
Suppression of proteoglycan-induced arthritis by anti-CD20 B cell depletion therapy is mediated by reduction in autoantibodies and CD4(+) T cell reactivity
Hamel, K; Doodes, P; Cao, YX; Wang, YM; Martinson, J; Dunn, R; Kehry, MR; Farkas, B; Finnegan, A
Journal of Immunology, 180(7): 4994-5003.

Journal of Immunology
Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis
Cassatella, MA; da Silva, GP; Tinazzi, I; Facchetti, F; Scapini, P; Calzetti, F; Tamassia, N; Wei, P; Nardelli, B; Roschke, V; Vecchi, A; Mantovani, A; Bambara, LM; Edwards, SW; Carletto, A
Journal of Immunology, 178(): 7325-7333.

Clinical and Experimental Rheumatology
Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients
Herman, S; Zurgil, N; Langevitz, P; Ehrenfeld, M; Deutsch, M
Clinical and Experimental Rheumatology, 26(2): 317-323.

Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease
Curcumin and autoimmune disease
Bright, JJ
Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, 595(): 425-451.

Arthritis and Rheumatism
Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis
Huang, QQ; Ma, YY; Adebayo, A; Pope, RM
Arthritis and Rheumatism, 56(7): 2192-2201.
Arthritis and Rheumatism
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis
Sigurdsson, S; Padyukov, L; Kurreeman, FAS; Liljedahl, U; Wiman, AC; Alfredsson, L; Toes, R; Ronnelid, J; Klareskog, L; Huizinga, TWJ; Alm, G; Syvanen, AC; Ronnblom, L
Arthritis and Rheumatism, 56(7): 2202-2210.
Genes and Immunity
Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity
Galligan, CL; Baig, E; Bykerk, V; Keystone, EC; Fish, EN
Genes and Immunity, 8(6): 480-491.
Inflammation Research
BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis
Zhang, L; Zhang, X; Wu, P; Li, H; Jin, S; Zhou, X; Li, Y; Ye, D; Chen, B; Wan, J
Inflammation Research, 57(4): 157-162.
International Immunopharmacology
Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: An effect independent of an anti-angiogenic action
Issekutz, AC; Sapru, K
International Immunopharmacology, 8(5): 708-716.
International Journal of Radiation Biology
Selectively induced death of macrophages in the synovial lining of murine knee joints using B-10-liposomes and boron neutron capture synovectomy
van Lent, PLEM; Krijger, GC; Hofkens, W; Nievaart, VA; Sloetjes, AW; Moss, RL; Koning, GA; van den Berg, WB
International Journal of Radiation Biology, 85(): 860-871.
Turkish Journal of Rheumatology
Elevated CD8(+) IL-17(+) Tc17 Levels and Their Correlation with Disease Activity in Patients with Rheumatoid Arthritis
Li, N; Han, J; Zhou, JR; Wang, JY; Zhang, J; Zheng, SG
Turkish Journal of Rheumatology, 28(2): 87-95.
p53 Contributes to Quercetin-Induced Apoptosis in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes
Xiao, P; Hao, YJ; Zhu, X; Wu, XJ
Inflammation, 36(2): 272-278.
British Journal of Pharmacology
Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis
Park, SY; Lee, SW; Baek, SH; Lee, CW; Lee, WS; Rhim, BY; Hong, KW; Kim, CD
British Journal of Pharmacology, 168(6): 1401-1411.
European Journal of Immunology
Loss of methylation at the IFNG promoter and CNS-1 is associated with the development of functional IFN-gamma memory in human CD4(+) T lymphocytes
Dong, J; Chang, HD; Ivascu, C; Qian, Y; Rezai, S; Okhrimenko, A; Cosmi, L; Maggi, L; Eckhardt, F; Wu, PH; Sieper, J; Alexander, T; Annunziato, F; Gossen, M; Li, J; Radbruch, A; Thiel, A
European Journal of Immunology, 43(3): 793-804.
JCR: Journal of Clinical Rheumatology
Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis
Genovese, MC
JCR: Journal of Clinical Rheumatology, 11(3): S45-S54.
PDF (725) | CrossRef
JCR: Journal of Clinical Rheumatology
Selective Costimulation Modulators: A Novel Approach for the Treatment of Rheumatoid Arthritis
Kremer, JM
JCR: Journal of Clinical Rheumatology, 11(3): S55-S62.
PDF (890) | CrossRef
Back to Top | Article Outline

rheumatoid arthritis; pathogenesis; autoimmunity; immune complexes; T cells; B cells; cytokines

© 2005 Lippincott Williams & Wilkins, Inc.

Follow Us!


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.